Radiopharmaceutical therapy in cancer: clinical advances and challenges
Radiopharmaceutical therapy (RPT) is emerging as a safe and effective targeted approach
to treating many types of cancer. In RPT, radiation is systemically or locally delivered using …
to treating many types of cancer. In RPT, radiation is systemically or locally delivered using …
Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy
L Emmett, K Willowson, J Violet, J Shin… - Journal of medical …, 2017 - Wiley Online Library
Prostate‐specific membrane antigen (PSMA) is a receptor on the surface of prostate cancer
cells that is revolutionising the way we image and treat men with prostate cancer. New small …
cells that is revolutionising the way we image and treat men with prostate cancer. New small …
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
C Kratochwil, WP Fendler, M Eiber, MS Hofman… - European journal of …, 2023 - Springer
Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically
significant prostate adenocarcinomas, and patients with target-positive disease can easily …
significant prostate adenocarcinomas, and patients with target-positive disease can easily …
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor-and PSMA-targeting ligands
K Sjögreen Gleisner, N Chouin, PM Gabina… - European journal of …, 2022 - Springer
The purpose of the EANM Dosimetry Committee is to provide recommendations and
guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals …
guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals …
EANM practice guideline for quantitative SPECT-CT
Abstract Purpose Quantitative SPECT-CT is a modality of growing importance with initial
developments in post radionuclide therapy dosimetry, and more recent expansion into bone …
developments in post radionuclide therapy dosimetry, and more recent expansion into bone …
ICRU REPORT 96, dosimetry-guided radiopharmaceutical therapy
The International Commission on Radiation Units and Measurements (ICRU), since its
inception in 1925, has had as its principal objective the development of internationally …
inception in 1925, has had as its principal objective the development of internationally …
A review of theranostics: perspectives on emerging approaches and clinical advancements
Theranostics is the combination of two approaches—diagnostics and therapeutics—applied
for decades in cancer imaging using radiopharmaceuticals or paired radiopharmaceuticals …
for decades in cancer imaging using radiopharmaceuticals or paired radiopharmaceuticals …
Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer: a prospective pilot study
BM Privé, SMB Peters, CHJ Muselaers, IM van Oort… - Clinical Cancer …, 2021 - AACR
Abstract Purpose:[177Lu] Lu-PSMA-617 radioligand therapy (177Lu-PSMA) is a novel
treatment for metastatic castration-resistant prostate cancer (mCRPC), which could also be …
treatment for metastatic castration-resistant prostate cancer (mCRPC), which could also be …
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
A Sundlöv, K Sjögreen-Gleisner, J Svensson… - European journal of …, 2017 - Springer
Purpose To present data from an interim analysis of a Phase II trial designed to determine
the feasibility, safety, and efficacy of individualising treatment based on renal dosimetry, by …
the feasibility, safety, and efficacy of individualising treatment based on renal dosimetry, by …
EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy
M Konijnenberg, K Herrmann, C Kobe… - European journal of …, 2021 - Springer
Executive Summary The EC Directive 2013/59/Euratom states in article 56 that exposures of
target volumes in nuclear medicine treatments shall be individually planned and their …
target volumes in nuclear medicine treatments shall be individually planned and their …